<table id="id_26875dca-d2a0-430d-b6e6-d0fc1bb36cfd" width="873.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_d267127c-f0a9-4e9d-b3fd-8b7f8dccc189">Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col width="34.5%"></col>
<col width="32.3%"></col>
<col width="33.2%"></col>
<tbody>
<tr id="id_3375d9fc-0269-45cb-9720-b23f1ca49dcd">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="bottom">Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="bottom">Effect on Concentration of Lamotrigine or Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="bottom">Clinical Comment</td>
</tr>
<tr id="id_42e69345-d70f-41fc-ba77-3860d981a126">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and <br/>150 mcg levonorgestrel</td>
<td align="left" stylecode="Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Rrule" valign="top">Decreased lamotrigine levels approximately 50%.</td>
</tr>
<tr id="id_43142226-3d65-4d1b-a0e4-1dfd45bd3e80">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">↓ levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decrease in levonorgestrel component by 19%.</td>
</tr>
<tr id="id_8c62b2ab-f7ed-4090-ae17-ec0f2a6b6661">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Carbamazepine (CBZ) and CBZ epoxide</td>
<td align="left" stylecode="Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Rrule" valign="top">Addition of carbamazepine decreases lamotrigine concentration approximately 40%.</td>
</tr>
<tr id="id_9432751f-90bc-48ff-9267-57d015f36077">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May increase CBZ epoxide levels.</td>
</tr>
<tr id="id_9dda8cc3-f1b0-4154-82a5-5e756c24770f">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenobarbital/Primidone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr id="id_4a688a3b-a4a5-43bd-b181-e4fd6150bcdf">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenytoin (PHT)</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%.</td>
</tr>
<tr id="id_7834c89f-4b96-4b4b-9ea7-dc3ac556f531">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifampin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine AUC approximately 40%.</td>
</tr>
<tr id="id_431f09fc-7e3c-4aa4-b403-42f9062c101e">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Valproate</td>
<td align="left" stylecode="Rrule" valign="top">↑ lamotrigine</td>
<td align="left" stylecode="Rrule" valign="top">Increased lamotrigine concentrations slightly more than 2-fold. <br/>
</td>
</tr>
<tr id="id_53f4aba0-b5e3-4f90-be67-ab83c5ce08eb">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? valproate</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients.</td>
</tr>
<tr id="id_c0243653-3e7a-4cfc-81f8-7aeff7dde833">
<td align="left" colspan="3" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>↓= Decreased (induces lamotrigine glucuronidation). </paragraph>
<paragraph>↑= Increased (inhibits lamotrigine glucuronidation). </paragraph>?= Conflicting data. </td>
</tr>
</tbody>
</table>